Unknown

Dataset Information

0

Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report.


ABSTRACT: Background:Pembrolizumab, an immune checkpoint inhibitor (ICI), is an IgG4 antibody that blocks interaction between programmed cell death protein 1 and programmed death-ligand 1. Myocarditis, an immune-related adverse event, has been reported in thymic epithelial tumours. Pembrolizumab has also been associated with development/exacerbation of myasthenia gravis (MG). Case summary:A 70-year-old woman with metastatic thymic cancer presented to the hospital with shortness of breath, 21?days after initiation of pembrolizumab. She was diagnosed with ICI-related myocarditis and was subsequently intubated due to respiratory failure. A dual-chamber pacemaker was placed due to complete heart block with asystole. Her troponin levels were elevated, an electrocardiogram was suspicious for myocardial infarction, but coronary angiogram revealed normal coronary arteries and endomyocardial biopsy confirmed the presence of myocarditis. Treatment was started with high-dose intravenous methylprednisolone and cardiovascular status improved. However, the patient was unable to be weaned from mechanical ventilation and tested positive for acetylcholine receptor binding/blocking antibodies due to de novo MG. After 50?days of hospitalization, she was discharged home in stable condition. A computed tomography scan was performed 6?weeks after pembrolizumab; results showed significant decrease/resolution of all measurable sites of metastatic disease in the lungs. Discussion:This is the first reported case of a patient developing single-agent pembrolizumab-induced myocarditis concomitant with new-onset MG after treatment for advanced thymic malignancy. Additional studies are needed to explore the association between myocarditis, MG, and ICI therapy.

SUBMITTER: Szuchan C 

PROVIDER: S-EPMC7319805 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report.

Szuchan Charles C   Elson Leah L   Alley Evan E   Leung Kevin K   Camargo Antonio Lewis AL   Elimimian Elizabeth E   Nahleh Zeina Z   Sadler Diego D  

European heart journal. Case reports 20200407 3


<h4>Background</h4>Pembrolizumab, an immune checkpoint inhibitor (ICI), is an IgG4 antibody that blocks interaction between programmed cell death protein 1 and programmed death-ligand 1. Myocarditis, an immune-related adverse event, has been reported in thymic epithelial tumours. Pembrolizumab has also been associated with development/exacerbation of myasthenia gravis (MG).<h4>Case summary</h4>A 70-year-old woman with metastatic thymic cancer presented to the hospital with shortness of breath, 2  ...[more]

Similar Datasets

| S-EPMC9939107 | biostudies-literature
| S-EPMC7378376 | biostudies-literature
| S-EPMC8649039 | biostudies-literature
| S-EPMC8637790 | biostudies-literature
| S-EPMC8415306 | biostudies-literature
| S-EPMC11353298 | biostudies-literature
| S-EPMC8761813 | biostudies-literature
| S-EPMC7292166 | biostudies-literature
| S-EPMC7283905 | biostudies-literature
| S-EPMC4096576 | biostudies-literature